Drew Rasco

8.3k total citations · 3 hit papers
192 papers, 4.1k citations indexed

About

Drew Rasco is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Drew Rasco has authored 192 papers receiving a total of 4.1k indexed citations (citations by other indexed papers that have themselves been cited), including 121 papers in Oncology, 63 papers in Molecular Biology and 51 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Drew Rasco's work include Cancer Immunotherapy and Biomarkers (57 papers), Monoclonal and Polyclonal Antibodies Research (24 papers) and Lung Cancer Treatments and Mutations (17 papers). Drew Rasco is often cited by papers focused on Cancer Immunotherapy and Biomarkers (57 papers), Monoclonal and Polyclonal Antibodies Research (24 papers) and Lung Cancer Treatments and Mutations (17 papers). Drew Rasco collaborates with scholars based in United States, Japan and Australia. Drew Rasco's co-authors include Kyriakos P. Papadopoulos, Amita Patnaik, Anthony W. Tolcher, Matthew H. Taylor, Corina E. Dutcus, Daniel E. Stepan, Vicky Makker, Emmett V. Schmidt, Robert Shumaker and Muralidhar Beeram and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Drew Rasco

184 papers receiving 4.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial

2019 360 citations Drew Rasco, Emmett V. Schmidt et al. profile →
Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors

2020 306 citations Drew Rasco et al. Journal of Clinical Oncology profile →
First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer☆

2021 196 citations Jiaxin Niu, Corinne Maurice‐Dror et al. Annals of Oncology profile →

Peers

Countries citing papers authored by Drew Rasco

Since Specialization

Citations

This map shows the geographic impact of Drew Rasco's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Drew Rasco with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Drew Rasco more than expected).

Fields of papers citing papers by Drew Rasco

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Drew Rasco. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Drew Rasco. The network helps show where Drew Rasco may publish in the future.

Co-authorship network of co-authors of Drew Rasco

This figure shows the co-authorship network connecting the top 25 collaborators of Drew Rasco. A scholar is included among the top collaborators of Drew Rasco based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Drew Rasco. Drew Rasco is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Abstract PO4-18-07: A dose escalation and cohort expansion study of the CDK9 inhibitor KB-0742 in triple negative breast cancer and transcriptionally addicted relapsed or refractory solid tumors 2024 ·Cancer Research ·Monica Mita, Alain C. Mita, Miguel A. Villalona‐Calero, Noah Federman, Drew Rasco, David R. Spigel, Jia Luo, Gregory M. Coté, Richard E. Cutler, Pavan Kumar, Crystal MacKenzie, Charles Y. Lin, Jorge DiMartino, Elizabeth Olek, Brian A. Van Tine	1
2	Safety and preliminary efficacy of EIK1001 in combination with pembrolizumab in participants with advanced solid tumors. 2024 ·Journal of Clinical Oncology ·Anthony W. Tolcher, Drew Rasco, Melissa L. Johnson, Manish R. Patel, Angela Alistar, Julia W. Cohen, (unknown), (unknown), Etah S. Kurland	2
3	Cln-619 (anti-MICA/B antibody) alone and in combination with pembrolizumab (P) for advanced solid tumors: Updated results of a Ph1 study. 2024 ·Journal of Clinical Oncology ·Ignacio Melero, Judy S. Wang, Martin Gutierrez, Erika Hamilton, Alexander I. Spira, Drew Rasco, John D. Powderly, Michael Millward, Sophia Frentzas, Rafał Stec, Manish Sharma, Mark Shackleton, Ana Arance, (unknown), Iwona Ługowska, Tracy Liu, Todd Shearer, Divya Gupta, Jeffrey A. Jones, Víctor Moreno	1
4	Results of a phase 1, dose-finding study of Debio 0123 as monotherapy in adult patients with advanced solid tumors: Safety, pharmacokinetic, and preliminary antitumor activity data. 2024 ·Journal of Clinical Oncology ·Kyriakos P. Papadopoulos, Manish Sharma, Reinhard Dummer, Ilaria Colombo, Egle Ramelyte, Leigh G. Seamon, Drew Rasco, (unknown), (unknown), Tri Tat, (unknown), (unknown), (unknown), Sandrine Micallef, Anne Bellon, (unknown), Anastasios Stathis	5
5	A first-in-human (FIH), phase 1/2, dose-escalation, dose-optimization, and dose-expansion study of PARP1-selective inhibitor IMP1734 in participants with advanced solid tumors. 2024 ·Journal of Clinical Oncology ·Guru Sonpavde, Justin Call, Gerald S. Falchook, (unknown), Drew Rasco, Lan Liu, Tiantian Niu, (unknown), Congcong Zhang, Jarema Kochan, Sam Rebello, (unknown), Viola Chen, Suba Krishnan	2
6	Safety, efficacy, and PKPD of 23ME-00610, a first-in-class anti-CD200R1 antibody, in patients with advanced neuroendocrine cancers: Results from a multi-center multi-country phase 1/2a expansion cohort. 2024 ·Journal of Clinical Oncology ·Drew Rasco, Albiruni Ryan Abdul Razak, Ali Raza Khaki, Alexander I. Spira, (unknown), Anh N. Diep, Maike Schmidt, (unknown), (unknown), Dylan M. Glatt	1
7	First-in-Human Study with Preclinical Data of BCL-2/BCL-xL Inhibitor Pelcitoclax in Locally Advanced or Metastatic Solid Tumors 2023 ·Clinical Cancer Research ·Nehal J. Lakhani, Drew Rasco, Hengbang Wang, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Matthew S. Davids, Dajun Yang, Yifan Zhai	13
8	Abstract P4-01-35: A Phase 1 Study of the Oral CDK7 Inhibitor XL102 as a Single Agent and in Combination Therapy in Patients With Advanced Solid Tumors (QUARTZ-101): Initial Results From the Dose-Escalation Stage 2023 ·Cancer Research ·Amita Patnaik, Minal Barve, Manali Bhave, Vivek Subbiah, Drew Rasco, (unknown), Jing Li, (unknown), Geoffrey I. Shapiro	1
9	Phase 1 study of the pan-RAF inhibitor tovorafenib in patients with advanced solid tumors followed by dose expansion in patients with metastatic melanoma 2023 ·Cancer Chemotherapy and Pharmacology ·Drew Rasco, Theresa Medina, Pippa Corrie, Anna C. Pavlick, Mark R. Middleton, Paul Lorigan, Chris J. Hebert, Ruth Plummer, James Larkin, Sanjiv S. Agarwala, Adil Daud, Jiaheng Qiu, Viviana Bozón, Michelle Kneissl, Elly Barry, Anthony J. Olszanski	24
10	128P A phase I dose escalation and expansion trial of LYT-200: A galectin-9 antibody +/- tislelizumab 2023 ·Immuno-Oncology Technology ·Gerald S. Falchook, Drew Rasco, Kyriakos P. Papadopoulos, Aparna R. Parikh, Amit Mahipal, Wells A. Messersmith, Gulam A. Manji, Siqing Fu, Eric J. Sherman, Deborah Fein, (unknown), (unknown), Jing Wang, Manish Sharma, David R. Spigel, (unknown), Zev A. Wainberg	1
11	Abstract CT174: First-in-class anti-CD200R1 antibody 23ME-00610 in patients with advanced solid malignancies: Phase 1 results 2023 ·Cancer Research ·Shivaani Kummar, (unknown), Scott A. Laurie, (unknown), (unknown), (unknown), Drew Rasco	1
12	A Phase I Dose-Escalation and Dose-Expansion Study of FCN-437c, a Novel CDK4/6 Inhibitor, in Patients with Advanced Solid Tumors 2022 ·Cancers ·Amita Patnaik, Erika Hamilton, (unknown), Drew Rasco, Lon Smith, Ya-Li Lee, (unknown), Wei Jiao, Ai‐Min Hui	1
13	1400P Vibostolimab, an anti-TIGIT antibody, as monotherapy and in combination with pembrolizumab in anti-PD-1/PD-L1-refractory NSCLC 2020 ·Annals of Oncology ·M-J. Ahn, Jiaxin Niu, Dongwook Kim, Drew Rasco, Kathryn F. Mileham, Hyun Cheol Chung, Ulka N. Vaishampayan, Corinne Maurice‐Dror, (unknown), Talia Golan, Elliot Chartash, (unknown), Jane Healy, Mohini Rajasagi, D.H. Lee	26
14	Phase I Study of CC-486 Alone and in Combination with Carboplatin or nab-Paclitaxel in Patients with Relapsed or Refractory Solid Tumors 2018 ·Clinical Cancer Research ·Daniel D. Von Hoff, Drew Rasco, Elisabeth I. Heath, Pamela N. Münster, Jan H.M. Schellens, Nicolás Isambert, Christophe Le Tourneau, Bert H. O’Neil, Ron H.J. Mathijssen, José A. López-Martín, W. Jeff Edenfield, Miguel Martín, Patricia LoRusso, Gordon L. Bray, Jorge DiMartino, Aaron Nguyen, Kejian Liu, Eric Laille, Johanna C. Bendell	27
15	A First-in-Human Study of Novel Cereblon Modulator Avadomide (CC-122) in Advanced Malignancies 2018 ·Clinical Cancer Research ·Drew Rasco, Kyriakos P. Papadopoulos, Michael Pourdehnad, Anita K. Gandhi, Patrick R. Hagner, Yan Li, Xin Wei, Rajesh Chopra, Kristen Hege, Jorge DiMartino, Kent C. Shih	74
16	Phase Ib Study of Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Combination with Pembrolizumab (MK-3475) in Patients with Advanced Solid Tumors 2017 ·Clinical Cancer Research ·Anthony W. Tolcher, Mario Sznol, Siwen Hu‐Lieskovan, Kyriakos P. Papadopoulos, Amita Patnaik, Drew Rasco, (unknown), Bo Huang, Dhiraj Gambhire, Ying Chen, Aron D. Thall, Nazima Pathan, Emmett V. Schmidt, Laura Q.M. Chow	183
17	Safety, Pharmacokinetics, and Pharmacodynamics of a Humanized Anti-Semaphorin 4D Antibody, in a First-In-Human Study of Patients with Advanced Solid Tumors 2015 ·Clinical Cancer Research ·Amita Patnaik, Glen J. Weiss, John E. Leonard, Drew Rasco, Jasgit C. Sachdev, Terrence L. Fisher, Laurie A. Winter, Christine Reilly, Robert B. Parker, (unknown), Lisa Blaydorn, Anthony W. Tolcher, Maurice Zauderer, Ramesh K. Ramanathan	50
18	Phase I First-in-Human Study of CUDC-101, a Multitargeted Inhibitor of HDACs, EGFR, and HER2 in Patients with Advanced Solid Tumors 2014 ·Clinical Cancer Research ·Toshio Shimizu, Patricia LoRusso, K. Papadopoulos, Amita Patnaik, Muralidhar Beeram, Lon Smith, Drew Rasco, Theresa A. Mays, (unknown), Anna Ma, Jing Wang, Robert J Laliberte, Maurizio Voi, Anthony W. Tolcher	67
19	A phase IB trial of the oral MEK inhibitor trametinib (GSK1120212) in combination with everolimus in patients with advanced solid tumors 2014 ·Annals of Oncology ·Anthony W. Tolcher, Johanna C. Bendell, Kyriakos P. Papadopoulos, Howard A. Burris, Amita Patnaik, Suzanne F. Jones, Drew Rasco, Donna S. Cox, M. Durante, Kevin M. Bellew, (unknown), (unknown), Jeffrey R. Infante	100
20	The Clinical Effect of the Dual-Targeting Strategy Involving PI3K/AKT/mTOR and RAS/MEK/ERK Pathways in Patients with Advanced Cancer 2012 ·Clinical Cancer Research ·Toshio Shimizu, Anthony W. Tolcher, Kyriakos P. Papadopoulos, Muralidhar Beeram, Drew Rasco, Lon Smith, Shelly Gunn, Leslie Smetzer, Theresa A. Mays, Brianne Kaiser, Michael J. Wick, Cathy Alvarez, (unknown), G. Mangold, Amita Patnaik	352

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact